Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.

about

Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.Clearing up potential misconceptions about the treatment of rheumatoid arthritis and the use of methotrexate in combination therapy.

P2860

Q47576115-F6B90611-8D13-4EB4-8546-05247C8F5410 Q55073318-67254AA6-FBC5-4C27-9A87-1B9F66839C3F

P2860

Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.

Item

http://www.wikidata.org/entity/Q38668352

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Comparative Risk of Harm Assoc ...... dulators: A Systematic Review.

@en

type

Item

label

Comparative Risk of Harm Assoc ...... dulators: A Systematic Review.

@en

prefLabel

Comparative Risk of Harm Assoc ...... dulators: A Systematic Review.

@en

P1476

Comparative Risk of Harm Assoc ...... odulators: A Systematic Review

@en

P2093

Alireza Mazinanian

http://www.w3.org/2001/XMLSchema#string

Anna Glechner

http://www.w3.org/2001/XMLSchema#string

Chandrasekar Gopalakrishnan

http://www.w3.org/2001/XMLSchema#string

Kylie J Thaler

http://www.w3.org/2001/XMLSchema#string

Marian S McDonagh

http://www.w3.org/2001/XMLSchema#string

Peter Mahlknecht

http://www.w3.org/2001/XMLSchema#string

Richard A Hansen

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

Current methods of the US Preventive Services Task Force: a review of the process.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.

Biologic therapy for autoimmune diseases: an update.

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.

Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.

P304

1078-1088

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ACR.22815

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gerald Gartlehner

Bita Mesgarpour

Rishi J Desai

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26663412

http://www.w3.org/2001/XMLSchema#string

Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.

about

P2860

P2860

Comparative Risk of Harm Associated With the Use of Targeted Immunomodulators: A Systematic Review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698